{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:25:26Z","timestamp":1777461926771,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:00:00Z","timestamp":1766793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ctrv.2025.103073","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T22:55:40Z","timestamp":1766876140000},"page":"103073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeted therapies in optic pathway gliomas"],"prefix":"10.1016","volume":"143","author":[{"given":"Edoardo","family":"Agosti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Paolo","family":"Panciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-2132","authenticated-orcid":false,"given":"Giuseppe","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia De","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Mapelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Tognetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Gagliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Maria","family":"Fontanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Zeppieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Ius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ctrv.2025.103073_b0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/cns.12.47","article-title":"Optic pathway gliomas: a review","volume":"2","author":"Fried","year":"2013","journal-title":"CNS Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103073_b0010","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.3390\/medicina60101687","article-title":"Optic nerve glioblastoma with optic chiasm involvement: a case report and a brief literature review","volume":"60","author":"Brok\u0101ns","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103073_b0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00401-015-1410-7","article-title":"Pilocytic astrocytoma: pathology, molecular mechanisms and markers","volume":"129","author":"Collins","year":"2015","journal-title":"Acta Neuropathol"},{"issue":"15","key":"10.1016\/j.ctrv.2025.103073_b0020","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.18632\/oncotarget.2194","article-title":"The NF1 gene revisited \u2013 from bench to bedside","volume":"5","author":"Yap","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.103073_b0025","article-title":"Phase I study of the BRAF inhibitor vemurafenib in combination with the mammalian target of rapamycin inhibitor everolimus in patients with BRAF-mutated malignancies. JCO Precis","volume":"2","author":"Subbiah","year":"2018","journal-title":"Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2025.103073_b0030","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","article-title":"Tandem duplication producing a novel oncogenic BRAF fusion gene","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103073_b0035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/neuonc\/noaa036","article-title":"Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference","volume":"22","author":"Packer","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2025.103073_b0040","article-title":"Implications of BRAF V600E mutation in gliomas: molecular considerations, prognostic value and treatment evolution","volume":"12","author":"Di Nunno","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103073_b0045","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/0883073815597756","article-title":"Improving care in pediatric neuro-oncology patients: an overview of the unique needs of children with brain tumors","volume":"31","author":"Fischer","year":"2016","journal-title":"J Child Neurol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103073_b0050","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.18632\/oncotarget.14004","article-title":"Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing","volume":"8","author":"Selt","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103073_b0055","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/path.2780","article-title":"MAPK pathway activation through BRAF gene fusion in pilocytic astrocytomas","volume":"222","author":"Jeuken","year":"2010","journal-title":"J Pathol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103073_b0060","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ctrv.2025.103073_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100857","article-title":"Pediatric low-grade glioma: targeted therapeutics and clinical trials in the molecular era","volume":"36","author":"Manoharan","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctrv.2025.103073_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1503894","article-title":"The role of MEK inhibition in pediatric low-grade gliomas","volume":"14","author":"Sheikh","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103073_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","article-title":"The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors","volume":"17","author":"Wei","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2025.103073_b0080","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103073_b0085","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103073_b0090","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/pbc.21881","article-title":"Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma","volume":"52","author":"Peyrl","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103073_b0095","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pbc.24142","article-title":"A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG)","volume":"60","author":"Yalon","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103073_b0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1001\/jamaophthalmol.2013.5819","article-title":"Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab","volume":"132","author":"Avery","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103073_b0105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00381-018-3739-4","article-title":"Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy","volume":"34","author":"Upadhyaya","year":"2018","journal-title":"Childs Nerv Syst"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103073_b0110","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/neuonc\/noaa071","article-title":"A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma","volume":"22","author":"Ullrich","year":"2020","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103073_b0115","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103073_b0120","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s00381-022-05571-y","article-title":"Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1","volume":"38","author":"Cantor","year":"2022","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103073_b0125","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/neuonc\/noac223","article-title":"A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK","volume":"25","author":"Green","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103073_b0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-023-04516-y","article-title":"Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components","volume":"166","author":"Bennebroek","year":"2024","journal-title":"J Neurooncol"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103073_b0135","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.22.01777","article-title":"Phase II randomized trial of lenalidomide in children with pilocytic astrocytomas and optic pathway gliomas","volume":"41","author":"Warren","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103073_b0140","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/neuonc\/not132","article-title":"Activation of mTORC1\/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target","volume":"15","author":"H\u00fctt-Cabezas","year":"2013","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103073_b0145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/neuonc\/nou329","article-title":"Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth","volume":"17","author":"Kaul","year":"2015","journal-title":"Neuro Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103073_b0150","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.devcel.2021.10.001","article-title":"Inhibition of ERK\/MAPK signaling as potential therapy to prevent optic pathway glioma in infants with neurofibromatosis type 1","volume":"56","author":"D\u2019Angelo","year":"2021","journal-title":"Dev Cell"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103073_b0155","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00381-021-05060-8","article-title":"Neurosurgical experience of managing optic pathway gliomas","volume":"37","author":"Hill","year":"2021","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103073_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3171\/2013.8.PEDS12546","article-title":"The role of surgery in optic pathway\/hypothalamic gliomas in children","volume":"13","author":"Goodden","year":"2014","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.ctrv.2025.103073_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.884250","article-title":"Neurosurgery for optic pathway glioma: optimizing multidisciplinary management","volume":"9","author":"Samples","year":"2022","journal-title":"Front Surg"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103073_b0170","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27351","article-title":"Carboplatin and vincristine neurotoxicity in the treatment of pediatric low-grade gliomas","volume":"65","author":"Rosca","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"10.1016\/j.ctrv.2025.103073_b0175","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3390\/cells12192380","article-title":"The present and future of optic pathway glioma therapy","volume":"12","author":"Dal Bello","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103073_b0180","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s11912-024-01527-4","article-title":"Past, present, and future therapeutic strategies for NF-1-associated tumors","volume":"26","author":"Na","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ctrv.2025.103073_b0185","article-title":"Response and resistance to BRAFV600E inhibition in gliomas: roadblocks ahead?","volume":"12","author":"Capogiri","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.103073_b0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fonc.2015.00054","article-title":"Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas","volume":"5","author":"Penman","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.103073_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1417484","article-title":"BRAF\/MEK inhibitors use for pediatric gliomas: real world experience from a resource-limited country","volume":"14","author":"Abu Laban","year":"2024","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103073_b0200","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.3390\/cancers11111790","article-title":"Optic pathway glioma in type 1 neurofibromatosis: review of its pathogenesis, diagnostic assessment, and treatment recommendations","volume":"11","author":"Cassina","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103073_b0205","doi-asserted-by":"crossref","first-page":"101","DOI":"10.14791\/btrt.2022.0006","article-title":"Recent update in pharmacological agents for optic pathway glioma","volume":"10","author":"Park","year":"2022","journal-title":"Brain Tumor Res Treat"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103073_b0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.65.6.8","article-title":"An overview of optic pathway glioma with neurofibromatosis type 1: pathogenesis, risk factors, and therapeutic strategies","volume":"65","author":"Chen","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103073_b0215","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0883073817739509","article-title":"Optic pathway gliomas in neurofibromatosis type 1","volume":"33","author":"Campen","year":"2018","journal-title":"J Child Neurol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103073_b0220","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/humu.22392","article-title":"NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience","volume":"34","author":"Sabbagh","year":"2013","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ctrv.2025.103073_b0225","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/CMAR.S362678","article-title":"Neurofibromatosis type 1-associated optic pathway gliomas: current challenges and future prospects","volume":"15","author":"Tang","year":"2023","journal-title":"Cancer Manag Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:56:53Z","timestamp":1770479813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":45,"alternative-id":["S0305737225001951"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103073","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapies in optic pathway gliomas","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103073"}}